Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (301-310 of 490) with videos related to

Pageof 49
Sort By:
Scientific Reports|April 16, 2024
Comparison of visual diagnostic accuracy of dermatologists practicing in Germany in patients with light skin and skin of colorFrederik Krefting, Maurice Moelleken, Stefanie Hölsken, et al.
Oncotarget|December 22, 2017
The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferationClaudia Dollt, Kathrin Becker, Julia Michel, et al.
Nature Neuroscience|December 4, 2014
PIEZO2 is required for mechanotransduction in human stem cell-derived touch receptorsKatrin Schrenk-Siemens, Hagen Wende, Vincenzo Prato, et al.
Oncoimmunology|March 3, 2020
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitorsSonja C S Simon, Xiaoying Hu, Jasper Panten, et al.
International Journal of Cancer|March 16, 2019
Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integrationDavid Schrama, Eva-Maria Sarosi, Christian Adam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology GroupSelma Ugurel, Dirk Schadendorf, Claudia Pföhler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2025
Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADORegNoah Zimmermann, Julian Kött, Tim Zell, et al.
Frontiers in Immunology|March 11, 2025
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADORegAndrea Forschner, Katharina C Kähler, Martin Gschnell, et al.
Nature Cancer|July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Nature Cancer|August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Pageof 49

Showing results (301-310 of 490) with videos related to

Sort By:
Pageof 49
Scientific Reports|April 16, 2024
Comparison of visual diagnostic accuracy of dermatologists practicing in Germany in patients with light skin and skin of colorFrederik Krefting, Maurice Moelleken, Stefanie Hölsken, et al.
Oncotarget|December 22, 2017
The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferationClaudia Dollt, Kathrin Becker, Julia Michel, et al.
Nature Neuroscience|December 4, 2014
PIEZO2 is required for mechanotransduction in human stem cell-derived touch receptorsKatrin Schrenk-Siemens, Hagen Wende, Vincenzo Prato, et al.
Oncoimmunology|March 3, 2020
Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitorsSonja C S Simon, Xiaoying Hu, Jasper Panten, et al.
International Journal of Cancer|March 16, 2019
Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integrationDavid Schrama, Eva-Maria Sarosi, Christian Adam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology GroupSelma Ugurel, Dirk Schadendorf, Claudia Pföhler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2025
Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADORegNoah Zimmermann, Julian Kött, Tim Zell, et al.
Frontiers in Immunology|March 11, 2025
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADORegAndrea Forschner, Katharina C Kähler, Martin Gschnell, et al.
Nature Cancer|July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Nature Cancer|August 14, 2023
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
Pageof 49